Immunophenotyping of Acute b Cell Lymphoblstic Leukemia

Immunophenotyping of Acute b Cell Lymphoblastic Leukemia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04084327

Enrollment

Registered

2019-09-10

Start date

2019-09-01

Completion date

2022-12-01

Last updated

2019-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukemia

Brief summary

To study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute iand its correlation with disease outcome

Detailed description

study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute from 2009 -2019 and its correlation with disease outcome

Interventions

OTHERstastical analysis

1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Months to 80 Years

Healthy volunteers

Inclusion criteria

* New cases admitted to SECI Who didn't receive treatment.Age above 1 years old.

Exclusion criteria

* Cases who received treatment Patients below 1 years old.Patients diagnosed as AML or T-ALL

Design outcomes

Primary

Measure	Time frame	Description
overall survival outcome	10 years	overall survival outcome
Disease-free survival outcome	10 years	Disease-free survival outcome
association of novel CD markers with old markers for assessment of disease outcome	10 years	association of novel CD markers with old markers for assessment of disease outcome

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026